Aclarion (ACON) Competitors $7.12 -0.29 (-3.91%) Closing price 07/18/2025 03:59 PM EasternExtended Trading$7.22 +0.09 (+1.33%) As of 07/18/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ACON vs. ENZ, BRTX, MGRX, BGLC, SSY, VSEE, ATIP, DHAC, NIVF, and OTRKShould you be buying Aclarion stock or one of its competitors? The main competitors of Aclarion include Enzo Biochem (ENZ), Biorestorative Therapies (BRTX), Mangoceuticals (MGRX), BioNexus Gene Lab (BGLC), SunLink Health Systems (SSY), VSee Health (VSEE), ATI Physical Therapy (ATIP), Digital Health Acquisition (DHAC), NewGenIvf Group (NIVF), and Ontrak (OTRK). These companies are all part of the "healthcare" industry. Aclarion vs. Its Competitors Enzo Biochem Biorestorative Therapies Mangoceuticals BioNexus Gene Lab SunLink Health Systems VSee Health ATI Physical Therapy Digital Health Acquisition NewGenIvf Group Ontrak Aclarion (NASDAQ:ACON) and Enzo Biochem (NYSE:ENZ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment. Do institutionals & insiders believe in ACON or ENZ? 7.5% of Aclarion shares are owned by institutional investors. Comparatively, 36.9% of Enzo Biochem shares are owned by institutional investors. 0.8% of Aclarion shares are owned by company insiders. Comparatively, 11.4% of Enzo Biochem shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts prefer ACON or ENZ? Aclarion currently has a consensus target price of $11,758.50, indicating a potential upside of 165,047.47%. Given Aclarion's stronger consensus rating and higher possible upside, analysts plainly believe Aclarion is more favorable than Enzo Biochem.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclarion 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Enzo Biochem 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation and earnings, ACON or ENZ? Aclarion has higher earnings, but lower revenue than Enzo Biochem. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAclarion$50K82.59-$6.99MN/AN/AEnzo Biochem$29.09M0.59-$26.08MN/AN/A Does the media prefer ACON or ENZ? In the previous week, Aclarion had 1 more articles in the media than Enzo Biochem. MarketBeat recorded 1 mentions for Aclarion and 0 mentions for Enzo Biochem. Aclarion's average media sentiment score of 0.00 equaled Enzo Biochem'saverage media sentiment score. Company Overall Sentiment Aclarion Neutral Enzo Biochem Neutral Is ACON or ENZ more profitable? Enzo Biochem has a net margin of -75.34% compared to Aclarion's net margin of -12,227.10%. Enzo Biochem's return on equity of -7.96% beat Aclarion's return on equity.Company Net Margins Return on Equity Return on Assets Aclarion-12,227.10% -126.89% -106.61% Enzo Biochem -75.34%-7.96%-5.49% Which has more volatility and risk, ACON or ENZ? Aclarion has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Comparatively, Enzo Biochem has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. SummaryAclarion and Enzo Biochem tied by winning 6 of the 12 factors compared between the two stocks. Get Aclarion News Delivered to You Automatically Sign up to receive the latest news and ratings for ACON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACON vs. The Competition Export to ExcelMetricAclarionMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.32M$6.98B$5.55B$9.40BDividend YieldN/A2.88%3.75%4.03%P/E RatioN/A26.7928.0119.82Price / Sales82.5936.65432.8198.20Price / CashN/A28.0836.1658.27Price / Book0.149.018.125.65Net Income-$6.99M$233.10M$3.25B$257.91M7 Day Performance-1.11%-0.15%1.68%3.38%1 Month Performance-2.86%1.22%7.30%11.11%1 Year Performance-99.73%23.63%32.89%18.99% Aclarion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACONAclarion2.1996 of 5 stars$7.12-3.9%$11,758.50+165,047.5%-99.7%$4.32M$50K0.007ENZEnzo BiochemN/A$0.33-14.8%N/A-71.5%$17.03M$29.09M0.00520Gap DownHigh Trading VolumeBRTXBiorestorative Therapies3.5428 of 5 stars$1.60-1.2%$18.00+1,025.0%-6.0%$12M$400K-1.097MGRXMangoceuticals0.9816 of 5 stars$1.52-0.7%N/A-98.1%$7.86M$511.08K-0.333BGLCBioNexus Gene Lab0.7449 of 5 stars$3.97-22.0%N/A-3.6%$7.15M$9.51M0.0030Gap DownSSYSunLink Health Systems1.7778 of 5 stars$0.97-0.5%N/A+41.4%$6.81M$31.09M6.911,376VSEEVSee Health0.8804 of 5 stars$1.38+13.1%$5.00+262.3%-77.1%$4.97MN/A0.00N/APositive NewsGap UpHigh Trading VolumeATIPATI Physical TherapyN/A$1.03flatN/AN/A$4.54M$741.86M-0.065,600DHACDigital Health AcquisitionN/A$1.22+3.4%N/A-77.4%$4.40MN/A0.002,021NIVFNewGenIvf GroupN/A$0.63+1.1%N/A-99.7%$2.74M$5.43M0.00N/APositive NewsGap UpOTRKOntrak2.527 of 5 stars$0.49+9.7%$24.00+4,828.1%-85.3%$2.06M$10.85M-0.03250High Trading Volume Related Companies and Tools Related Companies Enzo Biochem Competitors Biorestorative Therapies Competitors Mangoceuticals Competitors BioNexus Gene Lab Competitors SunLink Health Systems Competitors VSee Health Competitors ATI Physical Therapy Competitors Digital Health Acquisition Competitors NewGenIvf Group Competitors Ontrak Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACON) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclarion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclarion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
